Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition

Boehringer IngelheimAs part of a three-year global initiative to identify and support the most promising solutions to challenging health problems around the world, Boehringer Ingelheim and Ashoka's Changemakers® announced the launch of the "Making More Health" Competition.

This worldwide competition invites the most innovative models and solutions that are transforming the field of health today.The competition will recognize and award US $10,000 to each of three winners whose solutions are working to achieve individual, family, and community well-being.

The Making More Health competition seeks solutions that work along the entire continuum of health, from prevention and lifestyle, to detection and treatment. Eligible entries include those that increase access to quality health services and treatment; promote prevention, early detection, and diagnosis; empower individuals, families, and communities to address their health issues; or target vulnerable and underserved populations. Entries will be accepted until September 21, 2011.

"The Making More Health competition reflects Boehringer Ingelheim's commitment to supporting leadership and innovation in healthcare and to improving health for individuals, families, and communities," said Jean Scheftsik de Szolnok, Vice-President Southern Europe for Boehringer Ingelheim. "By sourcing new approaches to healthcare delivery, the competition will contribute to ensuring a sustainable future in which good health for everyone is possible."

Participants can submit competition entries through the www.changemakers.com/morehealth website where they can discuss and share ideas about different approaches to health, comment on entries, and vote for winners. An expert panel of judges, including Dr. Andreas Barner, chairman of the board of managing directors for Boehringer Ingelheim and Aman Bhandari, senior advisor to the CTO at the US Department of Health and Human Services, will select a pool of finalists, and the Changemakers online community will vote to determine the three winning entries.

"We are excited about the opportunity our partnership with Boehringer Ingelheim has offered to tap the drive and creativity of changemakers from around the globe and make their solutions visible to all who are interested in finding them," said Diana Wells, president of Ashoka. "Boehringer Ingelheim is taking an important leadership role in the sector by recognizing the value that surfacing community solutions for health is critical to their core business."

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing, and marketing novel products of high therapeutic value for human and veterinary medicine.

Social responsibility is a core element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of its global operations. Mutual cooperation and respect, as well as environmental protection and sustainability, are intrinsic values of all of Boehringer Ingelheim's endeavors.

About Ashoka's Changemakers
Ashoka's Changemakers is an online community of action that connects social entrepreneurs around the globe to share ideas, inspire, and mentor each other. Through its online collaborative competitions and open-source process, Changemakers.com is one of the world's most robust spaces for launching, discussing, and scaling ideas to solve the world's most pressing social problems. Changemakers builds on Ashoka's three-decade history and vision for an "Everyone a Changemaker" world by creating a place where the best ideas in social innovation can be shared, refined, and funded.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...